Latest news
Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program - Fierce BiotechFierce Biotech · Mon, 10 Aug 2026 09:04:01 GMTEnsoma sheds more staff, pauses preclinical programs to home in on lead gene therapy - Fierce BiotechFierce Biotech · Fri, 07 Aug 2026 15:16:34 GMTBioMarin axes $270M asset after missing phase 3 endpoint - Fierce BiotechFierce Biotech · Fri, 07 Aug 2026 13:10:41 GMTFierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat - Fierce PharmaFierce Pharma · Fri, 07 Aug 2026 12:35:10 GMTBioNTech brings in Sobi CEO—Chutes & Ladders - Fierce BiotechFierce Biotech · Fri, 07 Aug 2026 12:30:00 GMTThe Oral GLP-1 Tracker: Lilly's Foundayo builds scripts after disappointing Q2 - Fierce PharmaFierce Pharma · Fri, 07 Aug 2026 07:00:00 GMTUPDATED: Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle - Fierce PharmaFierce Pharma · Thu, 06 Aug 2026 20:41:48 GMTTakeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful - Fierce PharmaFierce Pharma · Thu, 06 Aug 2026 15:10:41 GMT